

Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at <a href="www.bccancer.bc.ca">www.bccancer.bc.ca</a> and according to acceptable standards of care

## PROTOCOL CODE: BRAVPTRAD

Page 1 of 2

DOCTOR'S ORDERS         Htcm         Wtkg         BSAm	n²	
REMINDER: Please ensure drug allergies and previous bleomycin are documented on	the Allergy & Alert Form	
DATE: To be given: Cycle #:		
Date of Previous Cycle:		
□ Delay treatment week(s) □ CBC & Diff, platelets day of treatment If ordered, may proceed with doses as written if within 96 hrs ANC greater than or equal to 1.5 x 10°/L, Platelets greater than or equal to 100 x 10°/L  Dose modification for: □ Hematology □ Other Toxicity  Proceed with treatment based on blood work from		
PREMEDICATIONS: Patient to take own supply. RN/Pharmacist to confirm		
<b>dexamethasone 8 mg</b> PO bid for 3 days, starting one day prior to DOCEtaxel treatment; patie prior to treatment		
Optional: Frozen gloves starting 15 minutes before DOCEtaxel infusion until 15 minutes after infusion; gloves should be changed after 45 minutes of wearing.  ☐ Other:	r end of DUCEtaxel	
**Have Hypersensitivity Reaction Tray and Protocol Available**		
CHEMOTHERAPY: (Note – continued over 2 pages)  ☐ CYCLE # 1		
DAY 1		
PERTuzumab 840 mg IV in 250 mL NS over 1 hour. Observe for 1 hour post-infusion		
DAY 2		
trastuzumab (HERCEPTIN) 8 mg/kg x kg = mg IV in 250 mL NS over 1 hour 30 minutes Observe for 1 hour post infusion. Do not substitute HERCEPTIN with trastuzumab biosimilar.		
DOCEtaxel 75 mg/m² x BSA = mg		
☐ Dose Modification: % = mg/m² x BSA = mg		
IV in 250 to 500 mL NS (use non-DEHP bag) over 1 hour (use non-DEHP tubing)		
<u>OR</u>		
CYCLE#2		
PERTuzumab 420 mg IV in 250 mL NS over 1 hour. Observe for 30 minutes to 1 hour post infusion.		
trastuzumab (HERCEPTIN) 6 mg/kg x kg = mg IV in NS 250 mL over N for 30 minutes post infusion. Do not substitute HERCEPTIN with trastuzumab biosimilar.	IS over 1 hour. Observe	
DOCEtaxel 75 mg/m² x BSA = mg		
☐ Dose Modification:% = mg/m² x BSA = mg		
IV in 250 to 500 mL NS (use non-DEHP bag) over 1 hour. (Use non-DEHP tubing)		
*** SEE PAGE 2 FOR CHEMOTHERAPY CYCLES 3 to 8***		
DOCTOR SIGNATURE:	UC	
	SIGNATURE:	



Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at <a href="www.bccancer.bc.ca">www.bccancer.bc.ca</a> and according to acceptable standards of care

PROTOCOL CODE: BRAVPTRAD

Page 2 of 2

DOCTOR'S ORDERS	
DATE:	
CHEMOTHERAPY: (Continued)  *** SEE PAGE 1 FOR CHEMOTHERAPY CYCLES 1 AND 2 ***	
OR  ☐ CYCLE # (Cycle 3 to 8)  PERTuzumab 420 mg IV in 250 mL NS over 30 minutes. Observe for 30 minutes to 1 hour post infusion.*  trastuzumab (HERCEPTIN) 6 mg/kg x kg = mg IV in 250 mL NS over 30 minutes.  Observe for 30 minutes post infusion*. Do not substitute HERCEPTIN with trastuzumab biosimilar.	
DOCEtaxel 75 mg/m² x BSA = mg  Dose Modification: % = mg/m² x BSA = mg  IV in 250 to 500 mL NS (use non-DEHP bag) over 1 hour. (Use non-DEHP tubing)	
OR ☐ CYCLE # (PERTuzumab and trastuzumab only) every ☐ three or ☐ four weeks (select one)	
PERTuzumab 420 mg IV in 250 mL NS over 30 minutes.	
trastuzumab (HERCEPTIN) 6 mg/kg x kg = mg IV in 250 mL NS over 30 minutes.	
*Observation period not required after 3 treatments with no reaction. Do not substitute HERCEP biosimilar.	ΓΙΝ with trastuzumab
acetaminophen 325 to 650 mg PO PRN for headache and rigors	
RETURN APPOINTMENT ORDERS	
Return in three or four weeks (circle one) weeks for Doctor and Cycle	
Return in weeks for Doctor and Cycle(s)	
Last Cycle. Return inweeks.	
Prior to cycles containing docetaxel (i.e., cycles 1 to 9 only): CBC & Diff, Platelets	
Prior to Cycle 4: Bilirubin, ALT, GGT, Alk Phos	
☐ CBC & Diff, platelets	
If clinically indicated:	
DOCTOR SIGNATURE:	UC SIGNATURE: